Valneva SE (VALN)

FR — Healthcare Sector
Peers: DAWN  ARVN  AVBP  ATXS  GERN  REPL  MGTX  MBX  DNA  IOVA 

Automate Your Wheel Strategy on VALN

With Tiblio's Option Bot, you can configure your own wheel strategy including VALN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VALN
  • Rev/Share 2.5519
  • Book/Share 2.4233
  • PB 3.1675
  • Debt/Equity 1.0563
  • CurrentRatio 2.2658
  • ROIC -0.131

 

  • MktCap 605690242.9919
  • FreeCF/Share -0.447
  • PFCF -17.6129
  • PE -8.8084
  • Debt/Assets 0.4167
  • DivYield 0
  • ROE -0.3527

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed VALN H.C. Wainwright -- Buy -- $18 Aug. 19, 2025

News

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
VALN
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), February 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. The Company will …

Read More
image for news Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

About Valneva SE (VALN)

  • IPO Date 2021-05-05
  • Website https://valneva.com
  • Industry Biotechnology
  • CEO Thomas Lingelbach
  • Employees 713
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.